©2014 Baishideng Publishing Group Inc.
World J Transplant. Jun 24, 2014; 4(2): 122-132
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.122
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.122
Table 7 Adverse events, causes of discontinuation and mortality n (%)
| Patients receiving everolimus (n = 74) | |
| Adverse events | 27 (36.5) |
| Dyslipidemia | 27 (36.5) |
| Infections | 9 (12.2) |
| Mucositis | 3 (4.1) |
| Diarrhoea | 1 (1.4) |
| Proteinuria | 1 (1.4) |
| Acute rejections post-conversion | 11 (14.9) |
| Causes of discontinuation | 21 (28.4) |
| Resolution of the cause of conversion | 6 ( 8.1) |
| Non-responding rejection and retransplantation | 6 ( 8.1) |
| Drug-related adverse events | 5 ( 6.7) |
| Intercurrent surgery | 4 ( 5.5 ) |
| Causes of mortality | 25 (33) |
| HCC recurrence during follow-up | 10 |
| De novo tumour | 4 |
| HCV recurrence | 4 |
| Chronic rejection | 4 |
| Sepsis | 1 |
| Graft-vs-host disease | 1 |
| Other causes | 1 |
- Citation: Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G, Charco R. Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant 2014; 4(2): 122-132
- URL: https://www.wjgnet.com/2220-3230/full/v4/i2/122.htm
- DOI: https://dx.doi.org/10.5500/wjt.v4.i2.122